Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene for Acne-Induced Hyperpigmentation (LEAP)
NCT05089708Phase 4Completed
- Sponsor
- Galderma
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Countries
- 2
01
Overview
A Phase 4 trial of CD5789 cream vehicle in acne vulgaris, Post-inflammatory hyperpigmentation (PIH), sponsored by Galderma. Started Dec 2021; status: completed.
02
Drugs
CD5789 cream vehicle
03
Conditions
acne vulgarisPost-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT05089708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089708.